echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Digestive System Information > Front Oncol: Hepatectomy (HR) vs. TACE in the treatment of intermediate-stage hepatocellular carcinoma (IM-HCC)

    Front Oncol: Hepatectomy (HR) vs. TACE in the treatment of intermediate-stage hepatocellular carcinoma (IM-HCC)

    • Last Update: 2021-11-11
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    The selection criteria for hepatectomy (HR) treatment for metaphase hepatocellular carcinoma (IM-HCC) is still controversial


    The selection criteria for hepatectomy (HR) treatment for metaphase hepatocellular carcinoma (IM-HCC) is still controversial


    The study divided 942 IM-HCC patients into HR group and TACE group


    The study divided 942 IM-HCC patients into HR group and TACE group


    A total of 942 HCC patients were enrolled, including 563 (59.


    The mOS of the entire cohort was 23.



    OS comparison before and after PSM

    Univariate analysis found that Child-Pugh classification (vs.


    Univariate analysis found that Child-Pugh classification (vs.



    Univariate analysis of OS related factors

    For those with a survival period of more than 6 months (HzR = 0.


    For those with a survival period of more than 6 months (HzR = 0.



    Comparison of OS in patients with different survival times

    In the stratified analysis, the OS benefit of HR treatment was observed in patients with higher LDH levels (p = 0.


    In the stratified analysis, the OS benefit of HR treatment was observed in patients with higher LDH levels (p = 0.




    LDH's influence on OS LDH's influence on OS

    The 1, 3, and 5-year survival rates in the TACE group were 76.
    9%, 52.
    7%, and 46.
    7%, respectively, while the HR group was 85.
    8%, 68.
    6%, and 63.
    3%, respectively
    .
    However, for patients with LDH levels <192 U/L, the 1, 3, and 5-year mortality rates of HR treatment are 2.
    89 times (95% CI = 0.
    71-11.
    81) and 1.
    20 times (95% CI = 0.
    54-respectively) that of TACE treatment.
    2.
    65), and 1.
    22 times (95% CI = 0.
    57-2.
    62)
    .

    The 1, 3, and 5-year survival rates in the TACE group were 76.
    9%, 52.
    7%, and 46.
    7%, respectively, while the HR group was 85.
    8%, 68.
    6%, and 63.
    3%, respectively
    .
    However, for patients with LDH levels <192 U/L, the 1, 3, and 5-year mortality rates of HR treatment are 2.
    89 times (95% CI = 0.
    71-11.
    81) and 1.
    20 times (95% CI = 0.
    54-respectively) that of TACE treatment.
    2.
    65), and 1.
    22 times (95% CI = 0.
    57-2.
    62)
    .

    In summary, studies have shown that for mid-stage HCC patients with LDH>192 U/L, hepatectomy (HR) is better than TACE
    .
    TACE may be suitable for patients with LDH level ≤192 U/L
    .

    In summary, studies have shown that for mid-stage HCC patients with LDH>192 U/L, hepatectomy (HR) is better than TACE
    .
    TACE may be suitable for patients with LDH level ≤192 U/L
    .
    Studies have shown that for patients with intermediate HCC with LDH>192 U/L, hepatectomy (HR) is better than TACE
    .
    TACE may be suitable for patients with LDH level ≤192 U/L
    .
    Studies have shown that for patients with intermediate HCC with LDH>192 U/L, hepatectomy (HR) is better than TACE
    .
    TACE may be suitable for patients with LDH level ≤192 U/L
    .

    Original source:

    Original source:

    Lu L, Zheng P, Wu Z and Chen X (2021) Hepatic Resection Versus Transarterial Chemoembolization for Intermediate-Stage Hepatocellular Carcinoma: A Cohort Study.
    Front.
    Oncol.
    11:618937.
    doi: 10.
    3389/fonc.
    2021.
    618937

    Lu L, Zheng P, Wu Z and Chen X (2021) Hepatic Resection Versus Transarterial Chemoembolization for Intermediate-Stage Hepatocellular Carcinoma:.
    .
    A Cohort Study Front Oncol 11:.
    618937 doi:.
    10.
    3389 / fonc.
    2021.
    618937

    in this message
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.